drugset / Trial / NCT00332696
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis
Timeline
- Start
- 2005-09
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 0.1 mg/ml | Intramuscular |
| Subject | Octreotide | Peptide | 30 mg | Intramuscular |
| Background | Methylprednisolone | Other / unclassified | 3 mg/kg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 4 mg/kg | Intravenous |